OrbiMed’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

OrbiMed’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,308,726	Closed	-$93.5M	–	131
2023 Q4	$93.5M	Hold	9,308,726	–	–	1.87%	14
2023 Q3	$26.8M	Buy	9,308,726 +275,000	+3%	+$1.01M	0.57%	58
2023 Q2	$34.4M	Sell	9,033,726 -464,048	-5%	-$1.3M	0.62%	51
2023 Q1	$17.7M	Buy	9,497,774 +1,612,904	+20%	+$3.37M	0.35%	71
2022 Q4	$18.1M	Hold	7,884,870	–	–	0.35%	66
2022 Q3	$25.4K	Hold	7,884,870	–	–	0.47%	64
2022 Q2	$43.4K	Hold	7,884,870	–	–	0.79%	42
2022 Q1	$18.4M	Hold	7,884,870	–	–	0.3%	69
2021 Q4	$47.6M	Hold	7,884,870	–	–	0.61%	50
2021 Q3	$109M	Hold	7,884,870	–	–	1.2%	26
2021 Q2	$103M	Hold	7,884,870	–	–	1.04%	31
2021 Q1	$121M	Buy	+7,884,870	New	+$186M	1.14%	26

OrbiMed's GRCL Position: Q1 2024 in Review

OrbiMed sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 9,308,726 shares — an estimated $93.5M sold.

OrbiMed first reported a position in GRCL in Q1 2021 and held it in 12 quarters. The position peaked at $121M in Q1 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

OrbiMed reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
OrbiMed sold 9,308,726 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $93.5M.
OrbiMed first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 12 quarters.
OrbiMed's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $121M in Q1 2021.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.